Published: February 13, 2006

EaglePicher Pharmaceutical Services, LLC Wins Major Contract Employing Nanotechnology With Further Expansion of Isolated cGMP Radiolabeling Capacity

Share This Story

Business Positioned for Unparalleled Growth

EaglePicher Pharmaceutical Services LLC ("EPPS") has welcomed the New Year with an exciting contract and the completion of the qualification of additional isolated radiolabeling capacity.

EPPS was recently awarded a contract for the development and supply under Current Good Manufacturing Practices (cGMP) of a product employing nanotechnology. A nanoparticle is a microscopic particle whose size is measured in nanometers. By employing nanotechnology, scientists believe drugs can be delivered to their target in a manner which is significantly more effective than traditional treatments. At present, a variety of nanoparticles are being investigated for many therapies including cancer treatment. Since the drug is delivered directly to the target, smaller doses of such cytotoxic drugs are needed for therapies utilizing this technology. "Nanotechnology is one of the most promising therapies in the fight against diseases such as cancer," states Sandeep Nimkar (PhD), EPPS' Director of Development. To date, very few products of this nature have emerged from discovery to be developed as products manufactured under cGMP.

"EPPS is proud to be at the forefront of developing an application which has the potential to improve the lives of so many individuals suffering from disease," says Nimkar. EPPS was able to win this contract because of its industry leading experience providing comprehensive support for programs specializing in development utilizing scale-up as well as its product support for clinical trials.

EPPS has also recently qualified additional isolated capacity for radiolabeling under cGMP. By combining decades of radiolabeling experience with sound quality systems and available isolation technology, EPPS has become the premier contract manufacturer and service provider for cGMP radiolabeling for ADME Studies and Microdosing. The expansion of these services complement EPPS' existing development, commercial API, and regulatory support capabilities to make EaglePicher Pharmaceutical Services a contract manufacturer that can support drug development from pre-clinical to commercial.

The EPPS team will be available to discuss these and the company's other exciting developments at the INFORMEX 2006 trade show in Orlando, Florida, from February 14-17th, 2006, at booth number 1358.

For more information about EaglePicher Pharmaceutical Services, access www.eaglepicher.com.

EaglePicher Pharmaceutical Services, LLC, a division of EaglePicher Technologies, LLC, has been a valued resource for the development and manufacture of APIs and the leading expert on cytotoxic/high-potency pharmaceuticals for more than 30 years. With broad experience, expert staff, and state-of-the-art equipment, labs and isolated suites, EaglePicher Pharmaceutical Services can take active ingredients from pre-clinical development through commercial production. The business specializes in the custom cGMP synthesis of pre-clinical, investigational and commercial APIs, radiolabeled compounds and cytotoxic/high-potency pharmaceuticals at FDA-inspected, USA-based facilities.

EaglePicher Incorporated, founded in 1843 and headquartered in Phoenix, Arizona, is a diversified manufacturer and marketer of innovative, advanced technology and industrial products and services for space, defense, environmental, automotive, medical, filtration, pharmaceutical, nuclear power, semiconductor and commercial applications worldwide. The company has 3,900 employees and operates more than 30 plants in the United States, Canada, Mexico and Germany. Additional information on the company is available on the Internet at www.eaglepicher.com.

This release contains statements which, to the extent that they are not recitations of historical fact, constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. These include any statements about future business operations, financial performance or market conditions. Such forward-looking information involves risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties are discussed in Eagle-Picher Holding's filings with the U.S. Securities and Exchange Commission.

EaglePicher(TM) is a trademark of EaglePicher Incorporated.